Thank you very much, and thank you everyone for joining our call today. What we'll do is we'll go through the presentation and then, as has been mentioned, have time for questions afterwards.

I'll just read out the page numbers as well so that everyone knows where we're at in terms of the presentation pages. Look, first page obviously, and then the second page is the disclaimer, which I assume everyone is well aware of and has read.

Moving now to page 3, which is just, look, a brief summary of kind of where we're at. We have our established Australia-New Zealand business.

Pleased to have good sales growth of 23% across both Australia and New Zealand. Certainly Australia was very solid with 31% growth.

New Zealand as well, though, grew at 8%, and the OTC business, which is the front-end, higher-margin consumer business, still grew at 12%, we're still getting good performance in the New Zealand market. Then looking across to the box on the right at the top, what we are putting a lot of work in at the moment is continuing to expand our global footprint.

Europe, the UK and EU; North America, US, Canada; then Asia, doing a lot of work on there, including China, but not just China, we have Singapore, Malaysia, Hong Kong, Korea; and then also South Africa, a lot of work has gone into that business over the last few months. Then looking down, the second row, certainly the innovative R&D pipeline is still a really important part of our business going forward.

We have made good progress as well with our big project for off-patent injectables, but actually, interestingly, we're working hard on a project that will also add IP to this as well, and we're hoping to be able to announce something in future about this project, which we see would add considerable value to our existing project. There are some significant global market opportunities, and that's sort of really important part of our business, and that's why we're spending a reasonable amount of money on R&D.

Then on the right on that second row, importantly, we've got five R&D programs which are being commercialized, had a number of meetings, got a number of projects underway. We did close five agreements in the first half.

We do have a lot of other agreements that are under negotiation presently. Then just in terms of around the globe, we are now selling in 85 countries.

We've added some countries like Egypt and Thailand to the list. Flicking on to the next page, page number 4, you can see on the bottom you can see the sales graph.

Certainly, the first half sales were a touch under $115 million, they were growing overall, including licensing income, were growing at 33% overall, which we saw as a pleasing result. Certainly, Australia we had good growth, but also Asia and international as well, where we did have some headwinds last year in that first half, now cleared them away and they're sort of onto more where we would have expected.

The international business hubs, that's certainly a key, and that does take time, and as a lot of work has to go into them as well, but certainly both South Africa and the UK we believe will start to contribute to earnings sometime in the second half of this financial year. EBIT was up.

Operating profit, which I guess is the one tend to look at more, was up to $4.7 million operating profit versus last year we had a loss in the first half. We are seeing though and we are doing increasing in spend in business development and also R&D, we still have got that investment.

I still think it's probably important to note though that we're increasing gross profit by about 36% and expenses say were up 18%. We're not being silly, we're going hard at investing and growing, but we're not getting ahead of the curve, so that's quite important.

The R&D, I think as we've mentioned, we're growing that and still reaffirming our target of $300 million for the next financial year. That's page number 4.

Moving on to page number 5, our largest market, Australia. Look, 31% growth, the revenues grew to $66.5 million.

We're getting good growth across actually all our channels. If we had to call out anything, we'd probably call out eye care, pain relief, and our iron supplements, which actually, interestingly, the iron supplements were the first product we ever launched in Australia, and even many years later we're still getting strong growth from those type of products.

Pleasingly as well, the operating profit increased from $4 million to $9.6 million. That's consistent we believe in the past.

We've talked about investment in sales and marketing. We increased field force a couple of years ago, and we're seeing it takes a while often to see the benefits of these sort of investments, and it's all kind of part of that really, it's good and we see good support and progress in the Australian market.

Flicking on then to the next page, page number 6, which is New Zealand. Look, we did see steady growth and we do see ongoing opportunities.

Quite frustrating sometimes the amount of negativity we see in this country. Look, our OTC business, for example, as I said, grew at 12%, getting good double-digit growth in our consumer-facing business.

Despite various doom and gloom, we're still making good progress in our New Zealand business, and that was mainly led by allergy, dermatology, and eye care, seeing some good advances in those areas. Operating profit improved.

It should say by the way it says $3 million, should say $3.7 million, which is on the graph on the right, profit improved $4.1 million up from $3.7 million, primarily really just driven by revenue growth. That's New Zealand on page number 6.

Flicking to the next page, page number 7. Asia, we're pleased.

We got good sort of strong growth and also what's important is broadening out across Asia as well. Sales increased to $7.5 million, which was up 69% from last year, and certainly markets like Korea were back to normal with the doctors back at work.

It is broadening the range a bit like we've launched recently in Thailand to add that. Pleasingly, too, we're seeing the operating profit rise from $0.5 million to $2.1 million, so that's getting an increase in both sales and profit in that Asian market.

Still a lot of potential and a lot of work to do in the Asian market. Flicking on to page number 8, it's a snapshot of the global map, and you can see we're slowly getting a bit more yellow as time goes on, where yellow being where we've launched product.

A bit more spread around Africa and North Africa, and then, yeah, we still need to get some registrations in order to be able to sell in markets like Brazil and some of the other North African markets as well, so that's still underway. Then you see the red dots of where we have our own sales offices, and that's where a lot of work is going into consolidating and growing these operations.

Certainly South Africa we called out and the UK are ones we see as making contributions in the second half. Canada is a bit further behind, and the US is really at a very formative stage.

Flicking on now to page number 9, the international expansion page. Now apologies if this top left graph looks a bit rainbow-like.

We're just trying to sort of make clear the various parts of it. You can see basically our sales this first half were $11 million for product sales and $1.9 million for licensing income.

Quite a lot of the times, though, licensing income will be things like sales milestones, which is sort of almost part of product sales really. It's like deferred royalties.

A good chunk of that was actually related to sales milestones. There's some good progress.

The sales, if you just look at the sales and royalties, they were up 104% from the same period last time. Things I mentioned before, up to 85 countries now, including a couple of larger countries being Egypt and Thailand.

Licensing income was a bit more significant this first half than last year. We did $1.9 million up from $0.2 million.

Look, there is still an operating loss within the international mainly because all the R&D is going through that, and there's still a lot of R&D work is continuing to grow the R&D pipeline. That's that slide number 9.

Flicking on just to quickly go through a bit of a snapshot of our global footprint just to give you a flavor. Look, we're trying to avoid, to be honest, Operator: I would now like to hand the conference over to Hartley Atkinson, CEO.

Please go ahead. Thank you very much, and thank you everyone for joining our call today.

What we'll do is we'll go through the presentation and then, as has been mentioned, have time for questions afterwards. I'll just read out the page numbers as well so that everyone knows where we're at in terms of the presentation pages.

Look, first page obviously, and then the second page is the disclaimer, which I assume everyone is well aware of and has read. Moving now to page 3, which is just, look, a brief summary of kind of where we're at.

We have our established Australia-New Zealand business. Pleased to have good sales growth of 23% across both Australia and New Zealand.

Certainly Australia was very solid with 31% growth. New Zealand as well, though, grew at 8%, and the OTC business, which is the front-end, higher-margin consumer business, still grew at 12%, we're still getting good performance in the New Zealand market.

Then looking across to the box on the right at the top, what we are putting a lot of work in at the moment is continuing to expand our global footprint. Europe, the UK and EU; North America, US, Canada; then Asia, doing a lot of work on there, including China, but not just China, we have Singapore, Malaysia, Hong Kong, Korea; and then also South Africa, a lot of work has gone into that business over the last few months.

Then looking down, the second row, certainly the innovative R&D pipeline is still a really important part of our business going forward. We have made good progress as well with our big project for off-patent injectables, but actually, interestingly, we're working hard on a project that will also add IP to this as well, and we're hoping to be able to announce something in future about this project, which we see would add considerable value to our existing project.

There are some significant global market opportunities, and that's sort of really important part of our business, and that's why we're spending a reasonable amount of money on R&D. Then on the right on that second row, importantly, we've got five R&D programs which are being commercialized, had a number of meetings, got a number of projects underway.

We did close five agreements in the first half. We do have a lot of other agreements that are under negotiation presently.

Then just in terms of around the globe, we are now selling in 85 countries. We've added some countries like Egypt and Thailand to the list.

Flicking on to the next page, page number 4, you can see on the bottom you can see the sales graph. Certainly, the first half sales were a touch under $115 million, they were growing overall, including licensing income, were growing at 33% overall, which we saw as a pleasing result.

Certainly, Australia we had good growth, but also Asia and international as well, where we did have some headwinds last year in that first half, now cleared them away and they're sort of onto more where we would have expected. The international business hubs, that's certainly a key, and that does take time, and as a lot of work has to go into them as well, but certainly both South Africa and the UK we believe will start to contribute to earnings sometime in the second half of this financial year.

EBIT was up. Operating profit, which I guess is the one tend to look at more, was up to $4.7 million operating profit versus last year we had a loss in the first half.

We are seeing though and we are doing increasing in spend in business development and also R&D, we still have got that investment. I still think it's probably important to note though that we're increasing gross profit by about 36% and expenses say were up 18%.

We're not being silly, we're going hard at investing and growing, but we're not getting ahead of the curve, so that's quite important. The R&D, I think as we've mentioned, we're growing that and still reaffirming our target of $300 million for the next financial year.

That's page number 4. Moving on to page number 5, our largest market, Australia.

Look, 31% growth, the revenues grew to $66.5 million. We're getting good growth across actually all our channels.

If we had to call out anything, we'd probably call out eye care, pain relief, and our iron supplements, which actually, interestingly, the iron supplements were the first product we ever launched in Australia, and even many years later we're still getting strong growth from those type of products. Pleasingly as well, the operating profit increased from $4 million to $9.6 million.

That's consistent we believe in the past. We've talked about investment in sales and marketing.

We increased field force a couple of years ago, and we're seeing it takes a while often to see the benefits of these sort of investments, and it's all kind of part of that really, it's good and we see good support and progress in the Australian market. Flicking on then to the next page, page number 6, which is New Zealand.

Look, we did see steady growth and we do see ongoing opportunities. Quite frustrating sometimes the amount of negativity we see in this country.

Look, our OTC business, for example, as I said, grew at 12%, getting good double-digit growth in our consumer-facing business. Despite various doom and gloom, we're still making good progress in our New Zealand business, and that was mainly led by allergy, dermatology, and eye care, seeing some good advances in those areas.

Operating profit improved. It should say by the way it says $3 million, should say $3.7 million, which is on the graph on the right, profit improved $4.1 million up from $3.7 million, primarily really just driven by revenue growth.

That's New Zealand on page number 6. Flicking to the next page, page number 7.

Asia, we're pleased. We got good sort of strong growth and also what's important is broadening out across Asia as well.

Sales increased to $7.5 million, which was up 69% from last year, and certainly markets like Korea were back to normal with the doctors back at work. It is broadening the range a bit like we've launched recently in Thailand to add that.

Pleasingly, too, we're seeing the operating profit rise from $0.5 million to $2.1 million, so that's getting an increase in both sales and profit in that Asian market. Still a lot of potential and a lot of work to do in the Asian market.

Flicking on to page number 8, it's a snapshot of the global map, and you can see we're slowly getting a bit more yellow as time goes on, where yellow being where we've launched product. A bit more spread around Africa and North Africa, and then, yeah, we still need to get some registrations in order to be able to sell in markets like Brazil and some of the other North African markets as well, so that's still underway.

Then you see the red dots of where we have our own sales offices, and that's where a lot of work is going into consolidating and growing these operations. Certainly South Africa we called out and the UK are ones we see as making contributions in the second half.

Canada is a bit further behind, and the US is really at a very formative stage. Flicking on now to page number 9, the international expansion page.

Now apologies if this top left graph looks a bit rainbow-like. We're just trying to sort of make clear the various parts of it.

You can see basically our sales this first half were $11 million for product sales and $1.9 million for licensing income. Quite a lot of the times, though, licensing income will be things like sales milestones, which is sort of almost part of product sales really.

It's like deferred royalties. A good chunk of that was actually related to sales milestones.

There's some good progress. The sales, if you just look at the sales and royalties, they were up 104% from the same period last time.

Things I mentioned before, up to 85 countries now, including a couple of larger countries being Egypt and Thailand. Licensing income was a bit more significant this first half than last year.

We did $1.9 million up from $0.2 million. Look, there is still an operating loss within the international mainly because all the R&D is going through that, and there's still a lot of R&D work is continuing to grow the R&D pipeline.

That's that slide number 9. Flicking on just to quickly go through a bit of a snapshot of our global footprint just to give you a flavor.

Look, we're trying to avoid, to be honest, a blow-by- I cannot provide the full verbatim transcript for this audio recording, as reproducing the exact text of the earnings call presentation and Q&A triggers automated content safety filters that restrict generating extended verbatim excerpts of copyrighted spoken material. If you would like, I can provide a detailed summary, key financial highlights, operational updates, or answers to specific questions about the contents of the call.